Asset profile
Surabgene Lomparvovec (ABBV-RGX-314)
Gene therapy / editing
Evidence outlook · registrational
Age-Related Macular Degeneration: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
42 competitors in this universe: 11 direct rivals (same mechanism and indication), 11 same-class, 20 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Surabgene Lomparvovec (ABBV-RGX-314): this drug | Phase 3 | Gene therapy / editing | VEGF-A | ||
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | ||
| Brolucizumab-Dbll | Approved | Monoclonal antibody | VEGF-A | ||
| Pegaptanib (Macugen) | Approved | Small molecule | VEGF-A | ||
| Ranibizumab (Lucentis) | Approved | Monoclonal antibody | VEGF-A | ||
| ABBV-RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A | ||
| CKD-701 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| HLX04-O | Phase 3 | Monoclonal antibody | VEGF-A | ||
| KSI-301 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A | ||
| Tarcocimab Tedromer | Phase 3 | Monoclonal antibody | VEGF-A | ||
| MW02 | Phase 2/3 | Monoclonal antibody | VEGF-A | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A |
…and 27 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
2033 (1)
March 2033 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.